LXRX Live signaler | Maksimer profitt med Getagraph.com

KJøP 122643 min ago

@ $3.29

Utstedt: 14 feb 2024 @ 19:44

Avkastning: -42.55%

Forrige signal: feb 14 - 15:31

Forrige signal: Selg

Avkastning: 4.44 %

Live Chart Being Loaded With Signals

Commentary (9 mai 2024 @ 22:00):

Stats
Dagens volum	1.63M
Gjennomsnittsvolum	4.54M
Markedsverdi	465.39M
EPS	$0 ( 2024-05-07 )
Neste inntjeningsdato	( $-0.180 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.28
ATR14	$0.00400 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-28	Swain Judith L	Buy	8 032	Common Stock
2024-04-28	Swain Judith L	Sell	8 032	Restricted Stock Units
2024-04-28	Sobecki Christopher J	Buy	8 032	Common Stock
2024-04-28	Sobecki Christopher J	Sell	8 032	Restricted Stock Units
2024-04-28	Lefkowitz Robert J Md	Buy	8 032	Common Stock

INSIDER POWER
77.52
Last 98 transactions
Buy: 8 163 755 \| Sell: 972 585

Volum Korrelasjon

Lang: 0.16 (neutral)

Kort: -0.59 (weak negative)

Signal:(59.829) Neutral

Lexicon Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
FAT	0.892
MORF	0.876
PCVX	0.869
ADVM	0.864
GANX	0.864
MREO	0.857
BNIXU	0.851
BASE	0.849
FCBP	0.839
CSX	0.835

10 Mest negative korrelasjoner
BFRI	-0.838
PSHG	-0.813
RTPY	-0.803

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Lexicon Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.12
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

0.19
( neutral )

Lexicon Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$1.20M
Bruttogevinst:	$565 000 (46.93 %)
EPS:	$-0.800

FY	2023
Omsetning:	$1.20M
Bruttogevinst:	$565 000 (46.93 %)
EPS:	$-0.800

FY	2022
Omsetning:	$139 000
Bruttogevinst:	$-288 000 (-207.19 %)
EPS:	$-0.620

FY	2021
Omsetning:	$298 000
Bruttogevinst:	$298 000 (100.00 %)
EPS:	$-0.602

Financial Reports:

No articles found.

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.